Login to Your Account

In The Clinic NEWS

With new science and true innovation, reimbursement should "take care of itself," Seres Therapeutics Inc.'s chief scientific officer (CSO) David Cook told BioWorld Today, on the brink of phase IIb data with SER-109 for recurrent Clostridium difficile infection (CDI).

Ampio Pharmaceuticals Inc. missed the primary endpoint in its second pivotal trial for Ampion, a candidate for treating osteoarthritis of the of the knee, tested under an FDA SPA.

Xcovery Inc. launched the phase III trial of X-396, its lead ALK inhibitor, as a first-line treatment in patients with ALK+ NSCLC.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: